期刊
MEDICAL CLINICS OF NORTH AMERICA
卷 97, 期 3, 页码 363-+出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.mcna.2013.01.001
关键词
International Work Group; Alzheimer disease; Diagnosis; Biomarkers
资金
- Pfizer
- Eisai
- MSD
- Merz
- Janssen-Cilag
- Novartis
- Lundbeck
- Roche
- Bayer
- Bristol-Myers Squibb
- GE Health Care
- GlaxoSmithKline
- Innogenetics
- Merck
- Genentech
- Nutricia
- Janssen Al
- Avid-Lilly
Alzheimer-type biomarker changes are identifiable in asymptomatic and mildly symptomatic predementia phases of Alzheimer disease (AD) and AD dementia. The International Work Group (IWG) guidelines for diagnosis identify a unified spectrum of 3 phases. The classic clinical feature that indicates AD is an episodic memory defect of the amnestic type. IWG criteria require biomarker support for the diagnoses of AD at any clinical stage. Pathophysiologic and topographic biomarkers are recognized. These criteria are proposed to allow highly specific diagnosis of AD and assist in identifying patients for clinical trials of AD-related treatments and other types of AD research.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据